The bill seeks to enhance protections for participants in the 340B drug discount program, specifically focusing on 340B-covered entities and their contract pharmacies. It introduces new definitions for "340B-covered entity" and "contract pharmacy" that align with federal law, ensuring that drug coverage reimburses these entities at rates comparable to those for non-340B entities. The legislation prohibits discriminatory practices in reimbursement terms, fees, audits, and other conditions that could disadvantage 340B entities. Additionally, it emphasizes patient choice by preventing payment entities from interfering with a patient's decision to receive medications from a 340B entity or its contract pharmacy.

Moreover, the bill establishes that manufacturers and distributors cannot obstruct the acquisition or delivery of 340B drugs to authorized pharmacies and cannot impose unnecessary data submission requirements on 340B grantees or their pharmacies. The Attorney General is granted jurisdiction to enforce these provisions, while the Board of Registration in Pharmacy is tasked with implementing necessary regulations. Overall, the legislation aims to create a fairer environment for 340B program participants, protect patient access to essential medications, and uphold the integrity of the 340B program.

Statutes affected:
Bill Text: 176B-1, 176G-1, 176I-1